newsfilter
← Latest News
FDA Press Releases·

FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

  • The FDA announced the Rare Disease Framework Initiative on October 14, 2026, to reimagine drug development for rare diseases by tailoring approaches to patient needs, product types, and small population realities.
  • A public meeting to solicit feedback from patients, advocates, & industry will be held on October 28 at the FDA's White Oak campus & facilitated by the Reagan-Udall Foundation.
  • HHS Secretary Robert F. Kennedy, Jr. stated the initiative aims to remove unnecessary barriers & accelerate treatments while maintaining rigorous standards under President Trump.
  • Acting FDA Commissioner Kyle Diamantas emphasized the need for a consistent, predictable, & innovative regulatory approach to address the lack of approved treatments for 95% of rare conditions.
  • The framework commits to providing clarity in decision-making, embedding patient voices early, leveraging external expertise, building shared resources, applying risk-based review approaches, & championing cutting-edge science.
  • The initiative is led by the FDA's Rare Disease Innovation Hub in partnership with the Office of the Commissioner, the Center for Biologics Evaluation and Research, & the Center for Drug Evaluation and Research.
  • Future input opportunities include sector-specific roundtables, Requests for Information, & internal feedback sessions to inform potential new guidance, regulatory revisions, & organizational changes.